Recent studies suggest that selective activators of specific subtypes of metabotropic glutamate receptors (mGluRs) have exciting potential for development of novel treatment strategies for a variety of psychiatric and neurological disorders, including Parkinson's disease, Alzheimer's disease, psychotic disorders, epilepsy, and others. Unfortunately, it has been difficult to develop compounds that act as selective agonists of specific mGluR subtypes that have properties that are likely to be suitable for development of therapeutic agents. However, over the past year, we and others have been highly successful in developing a novel approach to activation of mGluRs by developing highly selective allosteric potentiators of specific mGluR subtypes. These allosteric potentiators do not activate mGluRs directly but dramatically potentiate the response of these receptors, to glutamate. These compounds offer high selectivity for the targeted receptor and provide an exciting new approach to development of novel selective activators of specific mGluR or other G protein-coupled receptor subtypes. Interestingly, our preliminary studies suggest that multiple allosteric potentiators may interact with similar binding pockets that are conserved between mGluR subtypes. However, we have identified at least one novel potentiator of mGluRS that may act at a distinct site. Defining the precise domains of the receptors required for actions of these compounds and the mechanisms involved in allosteric potentiation of mGluRs will be important for further development of this approach to mGluR activation. Furthermore, a number of previous studies raise the possibility that allosteric potentiators could differentially regulate mGluR coupling to different signaling pathways or functional responses in different neuronal populations. However, the effects of allosteric potentiators on coupling of mGluRs to multiple signaling pathways and the physiological effects of these compounds have not been determined. We now propose a series of studies in which we will use site directed mutagenesis to rigorously define the domains and specific amino acids necessary for the function of allosteric potentiators at mGluR4 and mGluRS that we recently discovered. We will then perform a series of studies in which we determine the effects of these allosteric potentiators on coupling to different signaling pathways and electrophysiological responses to mGluR activation in native neuronal and glial cell populations. These studies will provide important information as to the impact of allosteric potentiators on mGluR function in different of neuronal circuits.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS031373-15
Application #
7363613
Study Section
Biophysics of Synapses, Channels, and Transporters Study Section (BSCT)
Program Officer
Stewart, Randall R
Project Start
1993-08-01
Project End
2010-07-14
Budget Start
2008-03-01
Budget End
2010-07-14
Support Year
15
Fiscal Year
2008
Total Cost
$336,575
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Doria, Juliana G; de Souza, Jessica M; Silva, Flavia R et al. (2018) The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease. J Neurochem 147:222-239
Yohn, Samantha E; Conn, P Jeffrey (2018) Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology 136:438-448
Stansley, Branden J; Conn, P Jeffrey (2018) The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr Opin Pharmacol 38:31-36
Joffe, Max E; Centanni, Samuel W; Jaramillo, Anel A et al. (2018) Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies. ACS Chem Neurosci 9:2188-2204
Gogliotti, Rocco G; Senter, Rebecca K; Fisher, Nicole M et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9:
Moehle, Mark S; Pancani, Tristano; Byun, Nellie et al. (2017) Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron 96:1358-1372.e4
Walker, Adam G; Sheffler, Douglas J; Lewis, Andrew S et al. (2017) Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology 42:2553-2566
Gogliotti, Rocco G; Senter, Rebecca K; Rook, Jerri M et al. (2016) mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Hum Mol Genet 25:1990-2004
Niswender, Colleen M; Jones, Carrie K; Lin, Xin et al. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chem Neurosci 7:1201-11
Senter, Rebecca K; Ghoshal, Ayan; Walker, Adam G et al. (2016) The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol 14:455-73

Showing the most recent 10 out of 132 publications